Healthcare
Live Price
Offline$5.50
+2.23% today
1Y Change
+154.63%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Savara Inc. (SVRA) is a Healthcare stock with a market cap of $1.05B and listed on NASDAQ. The stock last traded around $5.50 and up 154.6% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -10.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -10.4%, free cash flow -13.4% with operating margin 0.0% and ROIC -53.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SVRA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SVRA
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SVRA Max Drawdown
-31.99%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SVRA and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$43.0M
-12.7% YoY
Free Cash Flow
-$40.1M
-16.1% YoY
Revenue Growth
+0.0%
EPS Growth
-10.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -245K | -78M | -44M | -28M | -29M |
| Operating Income | -124M | -103M | -60M | -39M | -41M |
| EBITDA | -123M | -102M | -59M | -38M | -40M |
| Net Income | -119M | -96M | -55M | -38M | -43M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33M | 15M | 27M | 52M | 34M |
| Total Assets | 253M | 213M | 178M | 140M | 177M |
| Total Liabilities | 50M | 41M | 37M | 32M | 32M |
| Shareholder Equity | 203M | 171M | 140M | 108M | 144M |
| Total Debt | 30M | 27M | 26M | 26M | 26M |
| Net Debt | -3M | 12M | -94K | -26M | -8M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
40M
-16.0% YoY
Capital Expenditures
57K
-533.3% YoY
Free Cash Flow
40M
-16.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-84.0%
Debt / Equity
0.15x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.